Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALT001 for neurological repair in recovery-phase intracerebral hemorrhage
ChiCTR2600126337Phase 2Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- Jun 2026
- Modality
- Stem Cell Therapies → Cell Therapies, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in intracerebral hemorrhage (ICH) comparing ALT001 treatment group with Placebo control group (2 arms). Planned start Jun 2026; status: not yet recruiting.
02
Drugs
ALT001
03
Conditions
intracerebral hemorrhage (ICH)
Beyond the preview
Go deeper on ChiCTR2600126337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600126337.